Literature DB >> 21773884

Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis.

Jung-Yoon Choe1, Hwajeong Lee, Hyun-Young Jung, Sung-Hoon Park, Sang-Cheol Bae, Seong-Kyu Kim.   

Abstract

We investigated associations between the methylenetetrahydrofolate reductase (MTHFR) polymorphisms C677T and A1298C and methotrexate (MTX)-related toxicities in Korean patients with rheumatoid arthritis (RA) taking MTX. One hundred sixty-seven patients with RA were enrolled in a cross-sectional study and genotyped for the single-nucleotide polymorphisms C677T and A1298C in MTHFR. Alleles, genotypes, and haplotypes of the C677T and A1298C polymorphisms were not associated with specific MTX toxicities. However, among RA patients with the 1298CC genotype, the proportion who experienced at least one toxicity was significantly greater than the proportion of patients with 1298AA who did (P = 0.043). In addition, the proportion of patients with the 677C/1298A haplotype who experienced toxicity was greater than the proportion of those with 677C/1298C who did (P = 0.032, odds ratio = 2.085, 95% confidence interval 1.058-4.106). In this study, MTHFR polymorphisms were associated with MTX toxicities in Korean patients with RA. Further study for association of MTHFR polymorphisms with MTX toxicities should be needed in larger RA population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773884     DOI: 10.1007/s00296-011-1989-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis.

Authors:  R GUBNER; S AUGUST; V GINSBERG
Journal:  Am J Med Sci       Date:  1951-02       Impact factor: 2.378

2.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.

Authors:  C M Ulrich; Y Yasui; R Storb; M M Schubert; J L Wagner; J Bigler; K S Ariail; C L Keener; S Li; H Liu; F M Farin; J D Potter
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.

Authors:  A Wluka; R Buchbinder; A Mylvaganam; S Hall; A Harkness; D Lewis; G O Littlejohn; M H Miller; P F Ryan
Journal:  J Rheumatol       Date:  2000-08       Impact factor: 4.666

4.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.

Authors:  Wako Urano; Atsuo Taniguchi; Hisashi Yamanaka; Eiichi Tanaka; Hiroshi Nakajima; Yuko Matsuda; Hideto Akama; Yutaka Kitamura; Naoyuki Kamatani
Journal:  Pharmacogenetics       Date:  2002-04

5.  Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases.

Authors:  J P Mena; M Salazar-Páramo; L González-López; J I Gámez-Nava; L Sandoval-Ramirez; J D Sánchez; L E Figuera; F J Muñoz-Valle; M Vazquez del Mercado; I P Dávalos
Journal:  Pharmacogenomics J       Date:  2010-06-01       Impact factor: 3.550

6.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

Authors:  I Weisberg; P Tran; B Christensen; S Sibani; R Rozen
Journal:  Mol Genet Metab       Date:  1998-07       Impact factor: 4.797

7.  Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial.

Authors:  S L Morgan; J E Baggott; W H Vaughn; J S Austin; T A Veitch; J Y Lee; W J Koopman; C L Krumdieck; G S Alarcón
Journal:  Ann Intern Med       Date:  1994-12-01       Impact factor: 25.391

8.  Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.

Authors:  M E Weinblatt; B N Weissman; D E Holdsworth; P A Fraser; A L Maier; K R Falchuk; J S Coblyn
Journal:  Arthritis Rheum       Date:  1992-02

9.  Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene.

Authors:  Y Berkun; D Levartovsky; A Rubinow; H Orbach; S Aamar; T Grenader; I Abou Atta; D Mevorach; G Friedman; A Ben-Yehuda
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

10.  Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.

Authors:  Atsuo Taniguchi; Wako Urano; Eiichi Tanaka; Shiori Furihata; Shigeo Kamitsuji; Eisuke Inoue; Mariko Yamanaka; Hisashi Yamanaka; Naoyuki Kamatani
Journal:  Pharmacogenet Genomics       Date:  2007-06       Impact factor: 2.089

View more
  8 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis.

Authors:  Gwan Gyu Song; Sang-Cheol Bae; Young Ho Lee
Journal:  Clin Rheumatol       Date:  2014-05-03       Impact factor: 2.980

3.  No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.

Authors:  Wefa Boughrara; Ahmed Benzaoui; Meriem Aberkane; Fatima Zohra Moghtit; Samia Dorgham; Aicha Sarah Lardjam-Hetraf; Hadjer Ouhaibi-Djellouli; Elisabeth Petit Teixeira; Abdallah Boudjema
Journal:  Inflamm Res       Date:  2017-03-15       Impact factor: 4.575

4.  The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.

Authors:  Tomas Soukup; Martin Dosedel; Petr Pavek; Jana Nekvindova; Ivan Barvik; Iva Bubancova; Petr Bradna; Ales Antonin Kubena; Alejandro Fernández Carazo; Tomas Veleta; Jiri Vlcek
Journal:  Rheumatol Int       Date:  2015-01-25       Impact factor: 2.631

5.  Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis.

Authors:  O E Voron'ko; K K Baskaev; V V Sobolev; E V Denisova; I M Korsunskaya
Journal:  Bull Exp Biol Med       Date:  2022-02-17       Impact factor: 0.804

6.  Fatal methotrexate toxicity: could it have been avoided?

Authors:  Reva Tripathi; Preeta Kaur Chugh; Deepa Kaur Chugh; Vertika Verma; Y M Mala
Journal:  BMJ Case Rep       Date:  2013-06-12

Review 7.  Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Authors:  Qi Qiu; Jing Huang; Yang Lin; Xiaoming Shu; Huizheng Fan; Zhihua Tu; Youwen Zhou; Cheng Xiao
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis.

Authors:  Jing Huang; Huizhen Fan; Qi Qiu; Kunpeng Liu; Shuang Lv; Jiang Li; Hui Yang; Xiaoming Shu; Yuan Xu; Xiangchen Lu; Cheng Lu; Yunnan Zhang; Cheng Xiao
Journal:  Ther Adv Chronic Dis       Date:  2020-04-27       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.